Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Assembly Biosciences (ASMB) Current Leases (2019 - 2025)

Assembly Biosciences has reported Current Leases over the past 7 years, most recently at $569000.0 for Q4 2025.

  • Quarterly results put Current Leases at $569000.0 for Q4 2025, up 23.43% from a year ago — trailing twelve months through Dec 2025 was $569000.0 (up 23.43% YoY), and the annual figure for FY2025 was $569000.0, up 23.43%.
  • Current Leases for Q4 2025 was $569000.0 at Assembly Biosciences, up from $548000.0 in the prior quarter.
  • Over the last five years, Current Leases for ASMB hit a ceiling of $3.4 million in Q3 2022 and a floor of $461000.0 in Q4 2024.
  • Median Current Leases over the past 5 years was $1.5 million (2023), compared with a mean of $1.9 million.
  • Biggest five-year swings in Current Leases: plummeted 74.22% in 2023 and later surged 52.93% in 2024.
  • Assembly Biosciences' Current Leases stood at $3.2 million in 2021, then grew by 6.76% to $3.4 million in 2022, then tumbled by 63.73% to $1.2 million in 2023, then tumbled by 62.21% to $461000.0 in 2024, then increased by 23.43% to $569000.0 in 2025.
  • The last three reported values for Current Leases were $569000.0 (Q4 2025), $548000.0 (Q3 2025), and $533000.0 (Q2 2025) per Business Quant data.